GLP-1semaglutidetirzepatidecounterfeit drugsemergency medicine

EMJ paper flags counterfeit GLP-1 agonists as hidden sedation risk

Emergency physicians are urged to treat unregulated incretin use as an unmeasured variable when assessing aspiration and airway risk before procedural sedation.

By Maren Holt · Senior Reporter, GLP-1

Oct 12 20:00 ETSource: Emergency medicine journal : EMJ

The wire

01An Emergency Medicine Journal article argues that counterfeit and unregulated GLP-1 receptor agonists represent an unmeasured variable in emergency department procedural sedation risk assessment.
02Patients sourcing incretins outside the regulated supply chain may not disclose use or know their dose, complicating pre-sedation fasting and aspiration risk decisions.
03The piece is a commentary rather than a prospective study, and no incidence data for sedation complications in this group is established.

From the source

Counterfeit and unregulated GLP-1 receptor agonists: an unmeasured variable in emergency department procedural sedation risk
Emergency medicine journal : EMJ · 2026 Oct 13 · Ochani S et al.

Read at pubmed.ncbi.nlm.nih.gov

Source URL https://pubmed.ncbi.nlm.nih.gov/42869636/